Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Patrick Mooney
Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions
Shots: Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative  drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertension Patrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trial The interview gives an understanding of Spyglass’…
November 29, 2022
Viewpoints_Tim Clackson
Tim Clackson, President & CEO of Theseus Pharmaceuticals, Shares Insights on its Pan-Variant Inhibitor Therapies to Treat Cancer
Shots: Tim spoke about the development of THE-349, a fourth-generation small molecule for the treatment of EGFR-mutant NSCLC Tim also talked about Thesus’ other small molecule, THE-630 in gastrointestinal stromal tumors (GIST) being evaluated in a P-I/II dose-escalation and expansion study  The interview gives an understanding of how Thesus is developing different treatment options to…
November 28, 2022
Viewpoints_Dr. Navdeep Tangri_Helen Yeh
Dr. Navdeep Tangri & Helen Yeh Shares Insights from the Data Presented at ASN Kidney Week 2022 on the Importance of Earlier Screening & Diagnosis of Chronic Kidney Disease
Shots: Dr. Navdeep spoke about the data presented at the ASN Kidney Week 2022 emphasizing on the urgent need for early screening of chronic kidney disease Helen Yeh talked about the treatment of CKD with Farxiga. She also focused on the patient support programs by AstraZeneca for the early diagnosis and screening of patients The…
November 21, 2022
Viewpoints_Dr. Susana Banerjee
Dr. Susana Banerjee, Medical Oncologist at The Royal Marsden Shares Insights from the SOLO-1 P-III Trial of Lynparza in Patients with BRCA Mutated Ovarian Cancer
Shots: Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22 Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…
November 14, 2022
Viewpoints_Dr. Bill La Via
Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)
Shots: Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID) The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…
November 9, 2022
Viewpoints_Simon Portsmouth
Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections
Shots: Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infections He also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countries The interview summarizes how Shionogi is advancing by developing medicines to treat serious…
November 7, 2022
Viewpoints_Martin Kilsgård
Martin Kilsgård, Head of Product at Trialbee, Shares Insights from the Launch of Trialbee Honey™ Analytics at DPHARM 2022
Shots: Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honey™ platform He also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areas The interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…
November 2, 2022
Viewpoints_Natalie Shiff
Natalie Shiff, Associate Medical Director, Janssen Rheumatology Shares Insights from the FDA Approval of Stelara to Treat Pediatric Patients with Active Psoriatic Arthritis
Shots: Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis She also spoke about the patient support program that is executed by Janssen to support patients to get Stelara  The interview gives an understanding of how Janssen is advancing…
October 31, 2022
Load more